NOVOZYMES A/S financials
NOVOZYMES A/S
529900T6WNZXD2R3JW38 | Line item | 2026 | 2025 | 2025 |
|---|---|---|---|
| Income statement | |||
| Revenue | €1.12B | — | €1.08B |
| Cost of sales | €484.6M | — | €483.3M |
| Gross profit | €634.7M | — | €594.3M |
| Administrative expenses | €59.7M | — | €58.3M |
| Operating profit (EBIT) | €266.8M | — | €265.5M |
| Net finance income / (cost) | -€8.6M | — | -€19.3M |
| Profit before tax | €256.9M | — | €244.7M |
| Income tax expense | €57.8M | — | €58.7M |
| Profit for the year | €199.1M | — | €186.0M |
| — attributable to owners | €199.1M | — | €186.0M |
| Total comprehensive income | €324.5M | — | €66.9M |
| Per share | |||
| Basic EPS | €0.43 | — | €0.40 |
| Diluted EPS | €0.43 | — | €0.40 |
| Free cash flow / share | €0.19 | — | €0.13 |
| Cash flow statement | |||
| Net cash from operating activities | €167.1M | — | €106.4M |
| Income taxes paid | €30.0M | — | €30.2M |
| Net cash from investing activities | -€93.1M | — | -€38.3M |
| Purchase of PP&E (capex) | €79.1M | — | €45.4M |
| Purchase of intangibles | €14.0M | — | €9.8M |
| Net cash from financing activities | -€25.9M | — | -€102.1M |
| Dividends paid | €265.1M | — | €0 |
| Proceeds from borrowings | €41.3M | — | €26.6M |
| Repayments of borrowings | €1.54B | — | €113.1M |
| Net change in cash | €48.1M | — | -€34.0M |
| Balance sheet | |||
| Total assets | €16.52B | €16.35B | €15.06B |
| Non-current assets | €14.48B | €14.37B | €13.11B |
| Property, plant & equipment | €3.06B | €3.00B | €2.92B |
| Intangible assets & goodwill | €6.27B | €6.19B | €5.53B |
| Current assets | €2.05B | €1.98B | €1.95B |
| Inventories | €792.7M | €772.2M | €730.3M |
| Trade & other receivables | €756.4M | €716.5M | €741.6M |
| Cash & equivalents | €327.2M | €275.3M | €249.5M |
| Total equity | €10.92B | €10.86B | €11.23B |
| Non-current liabilities | €4.38B | €2.75B | €2.66B |
| Long-term borrowings | €2.92B | €1.30B | €1.27B |
| Current liabilities | €1.22B | €2.74B | €1.17B |
| Deferred tax liabilities | €1.31B | €1.32B | €1.25B |
| Derived metrics | |||
| Free cash flow | €88.0M | — | €61.0M |
| Operating margin | 23.8% | — | 24.6% |
| Net margin | 17.8% | — | 17.3% |
| Return on equity | 1.8% | — | 1.7% |
| Cash conversion ratio | 0.84× | — | 0.57× |
| Capex coverage | 2.11× | — | 2.34× |
| Other reported items | |||
| Changes In Equity | €64.4M | — | €54.7M |
| Comprehensive Income Attributable To Owners of Parent | €324.5M | — | €66.9M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €289.1M | €1.70B | €429.9M |
| Current Contract Assets | €16.5M | €35.9M | €10.3M |
| Current Contract Liabilities | €28.2M | €26.0M | €26.4M |
| Current Tax Assets Current | €7.9M | €46.0M | €81.4M |
| Current Tax Liabilities Current | €107.6M | €116.7M | €127.8M |
| Decrease Increase Through Tax On Sharebased Payment Transactions | €4.5M | — | €2.3M |
| Deferred Tax Assets | €244.8M | €242.2M | €272.3M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €3.8M | — | €3.5M |
| Equity and Liabilities | €16.52B | €16.35B | €15.06B |
| Gains Losses On Cash Flow Hedges Before Tax | -€8.8M | — | €18.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | €141.9M | — | -€137.5M |
| Increase Decrease In Cash and Cash Equivalents | €51.9M | — | -€30.5M |
| Increase Decrease In Working Capital | €206.2M | — | €260.8M |
| Increase Decrease Through Sharebased Payment Transactions | €4.7M | — | €5.7M |
| Intangible Assets Other Than Goodwill | €4.87B | €4.90B | €4.34B |
| Interest Paid Classified As Operating Activities | €22.9M | — | €16.4M |
| Interest Received Classified As Operating Activities | €4.5M | — | €6.2M |
| Investments In Associates Accounted For Using Equity Method | €16.2M | €17.5M | €22.7M |
| Issued Capital | €125.4M | €125.5M | €125.6M |
| Liabilities | €5.60B | €5.49B | €3.83B |
| Noncurrent Contract Liabilities | €76.6M | €79.9M | €98.0M |
| Noncurrent Provisions | €25.1M | €23.5M | €42.4M |
| Other Adjustments For Noncash Items | €222.6M | — | €221.6M |
| Other Comprehensive Income | €125.4M | — | -€119.1M |
| Other Current Financial Assets | €2.2M | €20.3M | €7.0M |
| Other Current Liabilities | €433.7M | €476.3M | €268.5M |
| Other Current Receivables | €142.8M | €117.0M | €125.8M |
| Other Noncurrent Financial Assets | €16.4M | €13.6M | €18.4M |
| Other Noncurrent Liabilities | €42.0M | €29.2M | €0 |
| Other Noncurrent Receivables | €6.0M | €5.9M | €5.8M |
| Other Operating Income Expense | €4.4M | — | €1.0M |
| Payments To Acquire Or Redeem Entitys Shares | €0 | — | €30.8M |
| Proceeds From Issue of Bonds Notes and Debentures | €1.69B | — | €0 |
| Proceeds From Sale Or Issue of Treasury Shares | €4.8M | — | €15.2M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €0 | — | €16.9M |
| Purchase of Treasury Shares | — | — | €30.8M |
| Research and Development Expense | €120.9M | — | €107.3M |
| Sale Or Issue of Treasury Shares | €4.8M | — | €15.2M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | -€1.3M | — | -€1.5M |
| Trade and Other Current Payables To Trade Suppliers | €363.8M | €420.8M | €317.6M |
| Undrawn Borrowing Facilities | €818.9M | €871.4M | — |
Every line item above is a fact tagged in NOVOZYMES A/S's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.